RCS - IGEA Pharma N.V. - IGEA ensures 'Alz1' supply for the EU market
RNS Number : 7269HIGEA Pharma N.V.07 December 2020
IGEA Pharma N.V. / Key word(s): Miscellaneous
IGEA ensures 'Alz1' supply for the EU market
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
IGEA ensures 'Alz1' supply for the EU market
Hoofddorp, the Netherlands, 6 December 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signature of an agreement with CSM Europe for the 'CE' compliant supply of Alz1. The distribution of Alz1 on a wholesale basis in selected EU markets is expected to start within the first half of 2021.
***
About IGEA
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content), and intends to launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound copper is an expected Alzheimer's and diabetes type II associated biomarker. Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore commercializes a COVID-19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. Med-tech products focuses on selected solutions and specialities. IGEA commercializes dry aerosol generators for air and inanimate environmental surfaces sanitization and air sterilization and purification devices.IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
Contacts
Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igeapharma.com
Patrick Pozzorini, CFO, +41 79 314 41 43, pozzorini@igeapharma.comDisclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.
Additional features:
File: 20201206 igea nv_press release
End of ad hoc announcement
Language:
English
Company:
IGEA Pharma N.V.
Siriusdreef 17
2123 WT Hoofddorp
Netherlands
Phone:
+31 23 568 9494
E-mail:
info@igearesearch.com
Internet:
www.igeapharma.nl
ISIN:
NL0012768675
Listed:
SIX Swiss Exchange
EQS News ID:
1153076
End of Announcement
EQS Group News Service
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNRAUBOVRRUUURRA
Recent news on PostNL NV
See all newsREG - Prosus NV Naspers Limited - Disposal of Avito Group
AnnouncementREG - Prosus NV Naspers Limited - Transaction in Own Shares
AnnouncementRCS - IGEA Pharma N.V. - THE LISTING OF THE NEW SHARES GRANTED
AnnouncementRCS - IGEA Pharma N.V. - IGEA EQUITY OFFER TO BLUE SKY NATURAL RESOURCES
AnnouncementRCS - IGEA Pharma N.V. - IGEA ANNOUNCES ANNUAL GENERAL MEETING RESOLUTIONS
Announcement